U.S. regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.The U.S. Food and Drug Management’s approval handed drugmaker Novo Nordisk an edge over rival Eli Lilly in the race to market an obesity pill. Lilly’s oral drug,orforglipron,is still under review.
Both pills are GLP-1 drugs that work like widely used injectables to mimic a natural hormone that controls appetite and feelings of fullness.
In recent years, Novo Nordisk’s injectable Wegovy and Lilly’s Zepbound have revolutionized obesity treatment globally and in the U.S.,where 100 million people have the chronic disease.
The Wegovy pills are expected to be available within weeks, company officials said. Availability of oral pills to treat obesity could expand the booming market for obesity treatments by broadening access and reducing costs, experts said.
About 1 in 8 Americans have used injectable GLP-1 drugs, according to a survey from KFF, a nonprofit health policy research group. But many more have trouble affording the costly shots.
“Ther’s an entire demographic that can benefit from the pills,” said Dr. Fatima Cody Stanford, a Massachusetts General Hospital obesity expert. “For me, it’s not just about who gets it across the finish line first. It’s about having these options available to patients.”
the Novo Nordisk obesity pill contains 25 milligrams of semaglutide. That’s the same ingredient in injectable
Weight loss Medications: Accessibility and affordability Expected to Improve
Table of Contents
December 23, 2024 – A key focus for the future of weight-loss treatments will be increasing access and lowering costs, making these medications available to a wider population. The current high price point of many weight-loss drugs is a significant barrier for many individuals, and experts believe increased competition and potentially new formulations could dramatically change this landscape. As one individual stated, a drug costing around $100 a month that demonstrates relative effectiveness would be a game-changer for many seeking treatment.
The Challenge of Cost
Currently, popular weight-loss medications like wegovy and Mounjaro can cost over $1,000 per month, putting them out of reach for the vast majority of people struggling with obesity. Obesity is a serious health concern, linked to a range of conditions including heart disease, type 2 diabetes, and certain types of cancer. Making effective treatments more affordable is therefore a public health priority.
Factors Driving Potential Price Reductions
Several factors are contributing to the expectation of increased affordability:
* Increased Competition: More pharmaceutical companies are entering the weight-loss drug market, developing both new medications and generic versions of existing ones. This competition is expected to drive down prices.Such as, Eli Lilly is a major player with Mounjaro,and other companies are actively researching and developing competing drugs.
* New Formulations & Delivery Methods: Research into option formulations, such as oral medications instead of injectables, and different delivery methods could potentially lower manufacturing costs and, consequently, prices.
* Insurance Coverage: As the understanding of obesity as a chronic disease grows, insurance companies are increasingly likely to cover weight-loss medications, reducing the out-of-pocket expense for patients. However, coverage often requires specific criteria to be met, such as a documented BMI and related health conditions.
* Generic options: As patents on existing drugs expire,generic manufacturers will be able to produce and sell lower-cost alternatives. This is a standard process in the pharmaceutical industry that significantly reduces drug prices.
Current Medications and Their Mechanisms
Several medications are currently approved for weight loss, working thru different mechanisms:
* GLP-1 Receptor Agonists (e.g., Wegovy, Mounjaro): These drugs mimic a natural hormone that regulates appetite and blood sugar levels. They promote feelings of fullness, leading to reduced food intake. Mayo Clinic provides a detailed overview of GLP-1 receptor agonists.
* Orlistat (Alli,Xenical): This medication works by blocking the absorption of fat from the diet.
* Naltrexone-bupropion (Contrave): This combination medication affects brain chemicals involved in appetite and cravings.
Key Takeaways
* Affordability is a major barrier: The high cost of current weight-loss medications limits access for many.
* Competition is increasing: More companies are developing weight-loss drugs, which should drive down prices.
* Insurance coverage is expanding: Obesity is increasingly recognized as a chronic disease, leading to better insurance coverage.
* New formulations are in development: Oral medications and alternative delivery methods could lower costs.
Looking Ahead
The coming years are likely to see significant changes in the weight-loss medication landscape. Increased accessibility and affordability will be crucial in addressing the global obesity epidemic and improving public health.Continued research and development will also focus on creating even more effective and well-tolerated treatments.
Disclaimer: The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Copyright 2024 The Associated Press. All rights reserved. This material may not be published,broadcast,rewritten or redistributed without permission.